Diazoxide for type 1 glycogen storage disease
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests a medicine called Diazoxide to see if it helps people with type 1 glycogen storage disease (a rare condition that makes it hard for the body to control blood sugar). It is only for patients treated at two specific hospitals in France.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must be diagnosed with type 1 glycogen storage disease (a rare condition affecting how the body uses stored sugar).
- You or your child is being treated at either CHRU Nancy or CHU Besançon hospitals in France.
- You have been told about the study and agree to let your medical data be used.
- If the patient is under 18, a parent or guardian must give permission.
- Your medical records must have enough information for the study to work with.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different diet strategies to help adults with GSDI (a metabolic condition also known as von Gierke disease) maintain stable blood sugars and avoid dangerous drops. It may help you learn how to better manage your condition through diet.
This study tests how well a home lactate meter and a standard blood sugar meter work for people with certain types of Glycogen Storage Disease (GSD Ia, Ib, or XI). If you or your child has one of these types, joining could help improve home monitoring.
This study tracks the health of people with type 3 Glycogen storage disease. It may help doctors understand the disease better and plan better care.
This Phase 2 study tests how certain channels in the brain help control how your body makes and releases sugar (glucose). It may help explain blood sugar problems in people with type 2 diabetes and healthy volunteers.
This study tests an experimental medicine called BEAM-301 for people with a specific form of glycogen storage disease type Ia (GSDIa). The goal is to see if it can help reduce dangerous low blood sugar episodes.
This study monitors the long-term health of people with Glycogen Storage Disease Type Ia who have already received the gene therapy DTX401, either in a previous clinical trial or after it was approved. The goal is to gather more information about their condition over time.
Hear when a new Glycogen Storage Disease Type I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.